3-(4-chlorophenyl)propyl methanesulfonate | 61440-60-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(4-chlorophenyl)propyl methanesulfonate
• 英文别名: methanesulfonic acid 3-(4-chlorophenyl)-propyl ester
• CAS: 61440-60-6
• 化学式: C₁₀H₁₃ClO₃S
• 分子量: 248.73
• InChiKey: NPANKSZVBOAPFP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  51.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(4-chlorophenyl)propyl methanesulfonate 在 sodium hydroxide 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 10.0h， 生成 3-(4-chlorophenyl)propane-1-thiol
  参考文献：
  名称：

  A New Series of Estrogen Receptor Modulators That Display Selectivity for Estrogen Receptor β

  摘要：

  A series of 1,3,5-triazine-based estrogen receptor (ER) modulators that are modestly selective for the ERbeta subtype are reported. Compound 1, which displayed modest potency and selectivity for ERbeta vs ERalpha, was identified via high-throughput screening utilizing an ERbeta SPA-based binding assay. Subsequent analogue preparation resulted in the identification of compounds such as 21 and 43 that display 25- to 30-fold selectivity for ERbeta with potencies in the 10-30 nM range. These compounds profile as full antagonists at ERbeta and weak partial agonists at ERalpha in a cell-based reporter gene assay. In addition, the X-ray crystal structure of compound 15 complexed with the ligand binding domain of ERbeta has been solved and was utilized in the design of more conformationally restrained analogues such as 31 in an attempt to increase selectivity for the ERbeta subtype.

  DOI：

  10.1021/jm020291h
• 作为产物：
  描述：

  4-氯氯苄 在 sodium tetrahydroborate 、 三氟化硼乙醚 、 sodium methylate 、 三乙胺 、 potassium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 为溶剂， 生成 3-(4-chlorophenyl)propyl methanesulfonate
  参考文献：
  名称：

  WO2024084379A1

  摘要：

  公开号：

文献信息

• Antilipidemic para-[aryl(alkyl or alkenyl)amino]-benzoic acid derivatives
  申请人：American Cyanamid Company

  公开号：US04185115A1

  公开（公告）日：1980-01-22

  Novel para-[aryl(alkyl or alkenyl)amino]benzoic acids, esters, pharmaceutically acceptable salts and pharmaceutical compositions thereof and a method of lowering serum lipid levels in mammals therewith.

  新型对-[芳基(烷基或烯基)氨基]苯甲酸，酯，药用盐及其药物组合物以及利用其在哺乳动物中降低血清脂质水平的方法。
• SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS
  申请人：Gilbert Eric J.

  公开号：US20130072468A1

  公开（公告）日：2013-03-21

  Compounds of Formula (I): or pharmaceutically acceptable salts, solvates, or esters thereof, are useful in treating diseases or conditions mediated by CB 1 receptors, such as metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, addiction (e.g., smoking cessation), gastrointestinal disorders, and cardiovascular conditions.

  式(I)的化合物或其药用可接受的盐、溶剂合物或酯类物，在治疗由CB1受体介导的疾病或症状方面具有用处，如代谢综合征和肥胖症、神经炎症性疾病、认知障碍和精神病、成瘾（如戒烟）、胃肠道疾病和心血管疾病。
• [EN] DEUTERATED PITOLISANT<br/>[FR] PITOLISANT DEUTÉRÉ
  申请人：CONCERT PHARMACEUTICALS INC

  公开号：WO2020092604A1

  公开（公告）日：2020-05-07

  This invention also provides compound of Formula (I) including pharmaceutical compositions comprising a compound of Formula (I) and a pharmaceutically acceptable carrier. This invention also provides the use of such compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering pitolisant. Some exemplary embodiments include a method of treating a disease or condition selected from narcolepsy, daytime sleepiness (particularly in subjects suffering from Parkinson's disease or obstructive sleep apnea syndrome), and cognitive defects in psychiatric conditions, the method comprising the step of administering to a subject in need thereof a pharmaceutically acceptable composition of the present invention.

  本发明还提供了一种包括化合物Formula (I)的复合物，其中包括一种Formula (I)化合物和药学上可接受的载体的药物组合物。本发明还提供了利用这些化合物和组合物在治疗疾病和病况的方法中的应用，这些疾病和病况通过给予pitolisant进行有益治疗。一些示例实施方式包括治疗疾病或病况的方法，所述疾病或病况选自嗜睡症、白天嗜睡（特别是患有帕金森病或阻塞性睡眠呼吸暂停综合征的患者）和精神病症中的认知缺陷，所述方法包括向需要的受试者给予本发明的药学上可接受的组合物。
• Structure-Based Design, Synthesis, and Structure−Activity Relationship Studies of Novel Non-nucleoside Adenosine Deaminase Inhibitors
  作者：Tadashi Terasaka、Takayoshi Kinoshita、Masako Kuno、Nobuo Seki、Kohichiro Tanaka、Isao Nakanishi

  DOI：10.1021/jm0306374

  日期：2004.7.1

  novel, highly potent non-nucleoside adenosine deaminase (ADA) inhibitor, 1-[(R)-1-hydroxy-4-(6-(3-(1-methylbenzimidazol-2-yl)propionylamino)indol-1-yl)-2- butyl]imidazole-4-carboxamide 1 (K(i)= 7.7 nM), which we recently reported. Structure-based drug design (SBDD) utilizing the crystal structure of the 1/ADA complex was performed in order to obtain structure-activity relationships (SAR) for this type

  我们在此公开了围绕新型高效非核苷腺苷脱氨酶（ADA）抑制剂1-[（R）-1-羟基-4-（6-（3-（1-甲基苯并咪唑-2-基）丙酰氨基] ）吲哚-1-基）-2-丁基]咪唑-4-羧酰胺1（K（i）= 7.7 nM），我们最近报道。进行了利用1 / ADA复合物晶体结构的基于结构的药物设计（SBDD），以便合理有效地获得此类化合物的结构-活性关系（SAR）。为了利用新形成的疏水性空间（F2），就结合活性和亚甲基-亚甲基的长度而言，允许用正丙基链（4b）或简单的苯环（4c）取代1的苯并咪唑环。间隔物被证明在二或三时是最佳的。就结合活性而言，用醚作为连接基取代酰胺也具有良好的耐受性，而且还改善了口服吸收（6a和6b）。最后，将吲哚-1-基转化为吲哚-3-基导致发现了一种新型的高效且可口服生物利用的ADA抑制剂1-[（R）-4-（5-（3-（4-氯苯基）丙氧基） ）-1-甲基吲哚-3-基）-1-羟基-2-丁基]咪唑-4甲酰胺8c。
• Arylalkylaminobenzoic acids
  申请人：American Cyanamid Company

  公开号：US04489094A1

  公开（公告）日：1984-12-18

  This disclosure describes novel [Bis(phenyl or substituted phenyl)alkyl]amino benzoic acids, esters, and derivatives thereof. These compounds are useful pharmaceutical agents for ameliorating atherosclerosis by inhibiting the formation and development of atherosclerotic lesions in the arterial walls of mammals.

  这份披露描述了新型的[双(苯基或取代苯基)烷基]氨基苯甲酸、酯及其衍生物。这些化合物是用于通过抑制哺乳动物动脉壁上的动脉粥样硬化病变的形成和发展来改善动脉粥样硬化的有用药物。